Liu Baoxing, Liu Xingyu, Xing Huifang, Ma Haibo, Lv Zhenyu, Zheng Yan, Xing Wenqun
Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Department of Geriatric Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Front Oncol. 2024 Feb 13;14:1349172. doi: 10.3389/fonc.2024.1349172. eCollection 2024.
Studies of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in resectable non-small-cell lung cancer (NSCLC) have been conducted. The purpose of our study was to evaluate the benefits of osimertinib as neoadjuvant therapy for resectable EGFR-mutated NSCLC.
This retrospective study evaluated patients with EGFR mutations in exon 19 or 21 who received targeted therapy with osimertinib (80 mg per day) before surgery between January 2019 and October 2023 in Henan Cancer Hospital.
Twenty patients were evaluated, all of whom underwent surgery. The rate of R0 resection was 100% (20/20). The objective response rate was 80% (16/20), and the disease control rate was 95% (19/20). Postoperative pathological analysis showed a 25% (5/20) major pathological response rate and 15% (3/20) pathological complete response rate. In total, 25% (5/20) developed adverse events (AEs), and the rate of grades 3-4 AEs was 10% (2/20). One patient experienced a grade 3 skin rash, and 1 patient experienced grade 3 diarrhea.
Osimertinib as neoadjuvant therapy for resectable EGFR-mutated NSCLC is safe and well tolerated. Osimertinib has the potential to improve the radical resection rate and prognosis.
已开展了表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于可切除非小细胞肺癌（NSCLC）的研究。我们研究的目的是评估奥希替尼作为可切除的EGFR突变NSCLC新辅助治疗的益处。
这项回顾性研究评估了2019年1月至2023年10月在河南省肿瘤医院术前接受奥希替尼（每日80毫克）靶向治疗的19外显子或21外显子EGFR突变患者。
评估了20例患者，所有患者均接受了手术。R0切除率为100%（20/20）。客观缓解率为80%（16/20），疾病控制率为95%（19/20）。术后病理分析显示主要病理缓解率为25%（5/20），病理完全缓解率为15%（3/20）。共有25%（5/20）发生不良事件（AE），3-4级AE的发生率为10%（2/20）。1例患者出现3级皮疹，1例患者出现3级腹泻。
奥希替尼作为可切除的EGFR突变NSCLC的新辅助治疗是安全的且耐受性良好。奥希替尼有提高根治性切除率和改善预后的潜力。
